跳至主要内容
临床试验/NL-OMON42299
NL-OMON42299已完成3 期

A randomised, double-blind, double-dummy, multi-site, phase III, single dose, 4-way cross-over pharmacodynamic study evaluating the efficacy of Bricanyl Turbuhaler M3 compared to Bricanyl Turbuhaler M2 by studying the protective effect on methacholine induced bronchoconstriction in patients with stable, mild to moderate asthma - BATMA

Astra Zeneca0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • - Female and male aged 18 and 65 years.
  • - At least 6 months of documented clinical diagnosis of asthma as defined by GINA 2012 or American Thoracic Society (Expert Panel Report 3 2007) prior to visit 1
  • - Stable asthmatics on SABA alone, on low dose ICS (200-400 µg budesonide corresponding) or on fixed combination of low ICS/LABA
  • - At the enrolment visit 1a, the visit baseline FEV1 must be >=80 % of that predicted normal (NHANES III). For LABA patients the visit baseline FEV1 must be >=80 % of that predicted normal (NHANES III) at both visit 1a and visit 1b. If not, the patient will be withdrawn from the study
  • - At the enrolment visits 1a or 1b (LABA patients only) and at the end of run-in period, visit 2, eligible patients should demonstrate an airway responsiveness to methacholine PC20 <8 mg/mL. If not, the patient will be withdrawn from the study
  • - Capable of using Turbuhaler inhalation device as judged by investigator.

排除标准

  • - Diagnosed with COPD or history of cystic fibrosis, bronchiectasis or other respiratory diseases
  • - Pregnancy, breast-feeding, lactation, or planned pregnancy during the study. Fertile women not using acceptable contraceptive measures
  • - Conditions which could alter airway reactivity to methacholine (e.g. pneumonia, upper respiratory tract infection, viral bronchitis and/or sinobronchitis) within past six weeks
  • - Exacerbation due to asthma or change in asthma medication during the last 3 months prior to enrolment
  • - Night time awakenings due to asthma symptoms on 2 consecutive nights during the last 4 weeks prior to enrolment
  • - Smokers 6 months prior to the study start or with a history of smoking of more than 10 pack years (e.g. 20 cigarettes/day for at least 10 years, or 10 cigarettes/day for at least 20 years, or equal).

研究者

发起方
Astra Zeneca

相似试验

进行中(未招募)
不适用
Comparing the efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg dose levels, to allow for a switch from Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3Asthma
EUCTR2014-001457-16-SEAstraZeneca AB60
进行中(未招募)
不适用
Comparing the efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg dose levels, to allow for a switch from Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3AsthmaMedDRA version: 17.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
EUCTR2014-001457-16-NLAstraZeneca AB60
进行中(未招募)
1 期
A comparative study on the efficacy of oral Rifamycin SV-MMX® 400 mg two times daily vs Rifamycin SV-MMX® 600 mg b.i.d. three times daily vs placebo (no active medication) in the treatment of acute uncomplicated diverticulitis (inflammation of protuberances of the bowel mucosa)
EUCTR2012-003300-13-ITDr. Falk Pharma GmbH375
进行中(未招募)
1 期
A comparative study on the efficacy of oral Rifamycin SV-MMX® 400 mg two times daily vs. Rifamycin SV-MMX® 600 mg three times daily vs. placebo (no active medication) in the treatment of acute uncomplicated diverticulitis (inflammation of protuberances of the bowel mucosa)
EUCTR2012-003300-13-RODr. Falk Pharma GmbH201
进行中(未招募)
1 期
A comparative study on the efficacy of oral Rifamycin SV-MMX® 400 mg two times daily vs. Rifamycin SV-MMX® 600 mg three times daily vs. placebo (no active medication) in the treatment of acute uncomplicated diverticulitis (inflammation of protuberances of the bowel mucosa)
EUCTR2012-003300-13-LVDr. Falk Pharma GmbH375